Lexeo Therapeutics Inc [NASDAQ: LXEO] plunged by -$0.05 during the normal trading session on while it closed the day at $7.64.
Lexeo Therapeutics Inc stock has also loss -6.83% of its value over the past 7 days. However, LXEO stock has declined by -36.86% in the 3 months of the year. Over the past six months meanwhile, it has lost -45.27% and lost -43.07% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for LXEO stock reached $252.59 million, with 26.65 million shares outstanding and 22.31 million shares in the current float. Compared to the average trading volume of 288.80K shares, LXEO reached a trading volume of 5963098 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Lexeo Therapeutics Inc [LXEO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXEO shares is $22.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXEO stock is a recommendation set at 1.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Lexeo Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 13, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 06, 2024, representing the official price target for Lexeo Therapeutics Inc stock. Previously, the target price had yet another raise to $20, while Stifel analysts kept a Buy rating on LXEO stock.
The Average True Range (ATR) for Lexeo Therapeutics Inc is set at 0.89 The Price to Book ratio for the last quarter was 1.53, with the Price to Cash per share for the same quarter was set at 5.29.
LXEO stock trade performance evaluation
Lexeo Therapeutics Inc [LXEO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.83. With this latest performance, LXEO shares dropped by -14.45% in over the last four-week period, additionally sinking by -45.27% over the last 6 months – not to mention a drop of -27.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXEO stock in for the last two-week period is set at 37.62, with the RSI for the last a single of trading hit 33.81, and the three-weeks RSI is set at 39.39 for Lexeo Therapeutics Inc [LXEO]. The present Moving Average for the last 50 days of trading for this stock 9.16, while it was recorded at 7.83 for the last single week of trading, and 12.99 for the last 200 days.
Lexeo Therapeutics Inc [LXEO]: An insightful look at the core fundamentals
Lexeo Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.38 and a Current Ratio set at 9.38.
Earnings per share (EPS) analysis for Lexeo Therapeutics Inc [LXEO] stock
With the latest financial reports released by the company, Lexeo Therapeutics Inc posted -12.36/share EPS, while the average EPS was predicted by analysts to be reported at -2.6/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.76. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXEO.
